These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor. Lose G; Nørgaard JP BJU Int; 2001 Jun; 87(9):767-73. PubMed ID: 11412211 [No Abstract] [Full Text] [Related]
11. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW; J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314 [TBL] [Abstract][Full Text] [Related]
12. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474 [TBL] [Abstract][Full Text] [Related]
13. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. Dmochowski RR; Nitti V; Staskin D; Luber K; Appell R; Davila GW World J Urol; 2005 Sep; 23(4):263-70. PubMed ID: 16151816 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Goldfischer ER; Sand PK; Thomas H; Peters-Gee J Neurourol Urodyn; 2015 Jan; 34(1):37-43. PubMed ID: 24133005 [TBL] [Abstract][Full Text] [Related]
16. [Instability of the detrusor muscle. Treatment with oxybutynin chloride (ditropan)]. Perales Cabanas L; Tallada Buñuel M; Romero Maroto J; Escribano Patiño G Actas Urol Esp; 1986; 10(6):481-6. PubMed ID: 3825651 [No Abstract] [Full Text] [Related]
17. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. Halaska M; Ralph G; Wiedemann A; Primus G; Ballering-Brühl B; Höfner K; Jonas U World J Urol; 2003 May; 20(6):392-9. PubMed ID: 12811500 [TBL] [Abstract][Full Text] [Related]
18. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655 [TBL] [Abstract][Full Text] [Related]
19. Advances in medical management of overactive bladder. Richelson E; Elliott DS Mayo Clin Proc; 2003 Jun; 78(6):681-3. PubMed ID: 12934775 [No Abstract] [Full Text] [Related]
20. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder. Ho C Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]